Drugs / ZF874
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT04443192 Comparator | Aug 2020 → Sep 2022 | alpha 1-antitrypsin deficiency | Z Factor Limited | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZF874 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04443192 ↗ |
| Action | Restore | “specifically designed to rescue the folding of the Z variant of alpha-1-antitrypsin (A1AT)” NCT04443192 ↗ |
| Modality | Small molecule | “ZF874 is a novel chemical chaperone” NCT04443192 ↗ |
| Route | Oral | “Single oral dose of ZF874 by mouth in the fasted state” NCT04443192 ↗ |